临床显著胸腔积液对美国退伍军人癌症、心力衰竭和肺炎患者生存的影响
该回顾性分析纳入2000至2020年住院的美国退伍军人,比较需引流的临床显著胸腔积液(PE)与无PE患者全因死亡率。在心力衰竭、癌症和肺炎三个诊断中,PE组中位生存期均显著低于无PE组,校正人口学和合并症后风险比不变,提示临床显著PE是独立死亡危险因素。
要点
- 临床显著胸腔积液与心力衰竭、癌症和肺炎患者全因死亡率升高独立相关
- 三个诊断中PE组中位生存期均显著低于无PE组
- 校正人口学和合并症后全因死亡风险比保持不变
核心结论
- 临床显著胸腔积液在因心力衰竭、癌症和肺炎入院的患者中与更高的全因死亡率独立相关。
研究设计与样本
- 使用ICD编码识别入院诊断为充血性心力衰竭、肺炎或癌症的患者。
- 将患者二分为临床显著胸腔积液(行PE引流)组和无PE组(包括无需引流PE及无PE者)。
- 比较两组全因死亡率,PE组34,707例,NO-PE组792,217例。
主要发现
- PE组全因死亡率显著高于无PE组。
- 心力衰竭患者中位生存期PE组1.51年(95%CI 1.40-1.61)vs NO-PE组3.23年(95%CI 3.21-3.26)。
- 癌症患者中位生存期PE组1.33年(95%CI 1.27-1.39)vs NO-PE组2.05年(95%CI 2.02-2.08)。
- 肺炎患者中位生存期PE组4.27年(95%CI 3.94-4.61)vs NO-PE组5.11年(95%CI 5.06-5.15)。
- 校正人口学和合并症后全因死亡风险比保持不变。
临床怎么用
- 在评估心力衰竭、癌症和肺炎患者预后时,应考虑临床显著胸腔积液与不良生存的关联。
- 在纵向队列生存分析中,需注意临床显著胸腔积液对生存的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous clinical data suggest that the presence of a pleural effusion is associated with poor survival. However, these studies were limited by either a small sample size or lack of an adequate control group. RESEARCH QUESTION: What is the impact of pleural effusion on survival in patients hospitalized with an admitting diagnosis of the 3 most common causes of pleural effusion: cancer, congestive heart failure, or pneumonia? STUDY DESIGN AND METHODS: This is a retrospective analysis of US veterans hospitalized between January 1, 2000 and December 31, 2020. International Classification of Diseases codes were used to identify patients with an admitting diagnosis of congestive heart failure (CHF), pneumonia, or cancer. Patients were dichotomized as having a clinically significant pleural effusion (PE) when a PE drainage was performed or not. The latter group included both patients who had a PE that was not clinically significant (did not require drainage) and those who did not have a PE at the time of index hospitalization (NO-PE). All-cause mortality was compared between the PE and NO-PE cohorts. RESULTS: We analyzed 34,707 patients in the PE group and 792,217 patients in the NO-PE group. Patients with PE had a significantly higher all-cause mortality compared with patients with no PE. The median survival time was significantly lower in PE group as compared with NO-PE group across all 3 diagnoses, CHF (PE, 1.51 years; 95% CI, 1.40-1.61 vs NO-PE, 3.23 years; 95% CI, 3.21-3.26), cancer (PE, 1.33 years; 95% CI, 1.27-1.39 vs NO-PE, 2.05 years; 95% CI, 2.02-2.08), and pneumonia (PE, 4.27 years; 95% CI, 3.94-4.61 vs NO-PE, 5.11 years; 95% CI, 5.06-5.15). The hazard ratios of all-cause mortality remained unchanged after adjusting for demographics and comorbidities. INTERPRETATION: The presence of a clinically significant PE was independently associated with higher all-cause mortality in patients with admitting diagnosis of CHF, cancer, and pneumonia. Clinicians and researchers should consider the association of CHF, cancer, and pneumonia with PEs when estimating the prognosis of individual patients and when assessing the survival of longitudinal cohorts.
引用
- Chopra A, Hu K, Gemoets DE, et al. The Impact of Clinically Significant Pleural Effusion on Survival of US Veterans With Cancer, Congestive Heart Failure, and Pneumonia: The Veterans Administration Lung Effusion Study. Chest. 2025. PMID: 39954847. doi:10.1016/j.chest.2025.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。